Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta

Immunotherapies against high-risk neuroblastoma (NB), using the anti-GD2 antibody (Ab) dinutuximab beta (DB), significantly improved patient survival. Ab-dependent cellular cytotoxicity (ADCC) is one of the main mechanisms of action and it is primarily mediated by NK cells. To further improve antitu...

Full description

Bibliographic Details
Main Authors: Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke, Simon Biskupski, Sascha Troschke-Meurer, Justus Leopold, Alexander Zikoridse, Holger N. Lode
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
neuroblastoma
immunotherapy
NK cells
dinutuximab beta
TIGIT
PD-L1
Online Access:https://www.mdpi.com/2072-6694/15/13/3317

Internet

https://www.mdpi.com/2072-6694/15/13/3317

Similar Items